Physician profile
Gerald William Hull
NPI 1639130628
$3,925.22
in general payments reported to CMS, 2019-2025
37 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $444 · 2021: $922 · 2022: $492 · 2023: $656 · 2024: $439 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $761.82 | 2020-2025 | Speedicath |
| Abbvie INC. | $550.66 | 2019-2025 | |
| Astellas Pharma US INC | $382.10 | 2019-2025 | Myrbetriq, Xtandi |
| Histosonics, INC. | $314.04 | 2024-2025 | |
| Procept Biorobotics Corporation | $302.40 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Janssen Biotech, INC. | $299.76 | 2019-2025 | Erleada |
| Antares Pharma, INC. | $286.50 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $151.02 | 2019-2023 | |
| Boston Scientific Corporation | $99.97 | 2022-2025 | Ams 700, Solyx Sis System |
| Merck Sharp & Dohme LLC | $78.11 | 2021-2022 | |
| Olympus America INC. | $63.63 | 2022-2025 | Itind System |
| Clarus Therapeutics INC. | $60.63 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $58.46 | 2020-2021 | |
| Smith+Nephew, INC. | $56.56 | 2020-2023 | Stravix |
| Astrazeneca Pharmaceuticals LP | $44.83 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $33.49 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $30.83 | 2021-2023 | |
| Urovant Sciences INC | $29.34 | 2021-2022 | |
| Halozyme INC | $28.09 | 2023 | |
| 180 Medical, INC. | $26.45 | 2023 | Gentlecath Glide |
| Axonics, INC. | $24.03 | 2024 | Bulkamid, Axonics |
| Biotissue Holdings INC. | $21.23 | 2023 | |
| Medtronic, INC. | $19.71 | 2025 | Interstim |
| Baxter Healthcare | $18.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.87 | 2022 | |
| Genzyme Corporation | $17.55 | 2022 | |
| Davol INC. | $15.23 | 2025 | Arista |
| Progenics Pharmaceuticals, INC. | $14.64 | 2025 | |
| Tolmar, INC. | $14.41 | 2024 | |
| Angiodynamics, INC. | $13.95 | 2025 | Nanoknife |
| Urogen Pharma, INC. | $13.91 | 2023 | Jelmyto |
| Blue Earth Diagnostics | $13.81 | 2023 | |
| Convatec INC. | $13.21 | 2021 | |
| Laborie Medical Technologies Corp. | $13.20 | 2025 | |
| Baudax Bio INC. | $12.74 | 2020 | |
| Travere Therapeutics, INC. | $12.63 | 2019 | |
| Ambu INC. | $9.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.